Document is current
Any future updates will be listed below
-
Authors
Wakefield, Claire E. https://orcid.org/0000-0001-7704-7067
Hetherington, Kate https://orcid.org/0000-0002-5457-5462
Robertson, Eden G. https://orcid.org/0000-0001-9395-7896
Donoghoe, Mark W. https://orcid.org/0000-0003-0212-6443
Hunter, Jacqueline D. https://orcid.org/0000-0002-2051-0396
Vetsch, Janine https://orcid.org/0000-0002-5564-7093
Marron, Jonathan M. https://orcid.org/0000-0001-8935-8524
Tucker, Katherine M. https://orcid.org/0000-0002-7180-6576
Marshall, Glenn M. https://orcid.org/0000-0002-2503-0762
Broom, Alexander
Haber, Michelle
Tyrrell, Vanessa https://orcid.org/0000-0002-5162-517X
Malkin, David
Lau, Loretta https://orcid.org/0000-0002-3172-0970
Mateos, Marion K. https://orcid.org/0000-0002-2763-5853
O’Brien, Tracey A.
Ziegler, David S. https://orcid.org/0000-0001-7451-7916
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (APP2008300)
Cancer Institute NSW (2021/TPG2112, ECF181430)
Foundation for the National Institutes of Health (R01HG012247-01)
- License Information
-
More Information
Article History
Received: 12 April 2023
Revised: 1 September 2023
Accepted: 5 September 2023
First Online: 19 September 2023
Competing interests
: DSZ reports consulting/advisory board fees from Bayer, Astra Zeneca, Accendatech, Novartis, Day One, FivePhusion, Amgen, Alexion, and Norgine. JMM has received an honorarium for serving on the Ethics Advisory Board for Partner Therapeutics and an honorarium for a lecture delivered to Sanofi-Genzyme Global Oncology. All other authors have no interests to declare.
: We received ethics and governance approval to conduct this study as part of PRISM-Impact, approved by Hunter New England Human Research Ethics Committee (HREC/17/HNE/29). Informed consent was obtained from all subjects involved in the study. This study was conducted in accordance with the Declaration of Helsinki.
